使用前列腺特异性膜抗原靶向PET/CT监测前列腺癌与肝细胞癌双癌患者的治疗
本病例报告描述一名70岁男性前列腺癌患者,在计划使用18F-PSMA1007行PSMA PET/CT时因肝脏摄取及磁共振相应发现确诊肝细胞癌(G1)。患者随后接受前列腺癌抗激素治疗及肝细胞癌局部区域治疗,随访PSMA靶向PET/CT显示前列腺癌相关治疗持久缓解,而肝脏病灶进展。
要点
- PSMA靶向PET/CT可同时评估前列腺癌与肝细胞癌的疾病范围。
- 随访PSMA靶向PET/CT显示前列腺癌治疗持久缓解而肝脏病灶进展。
- 该分子影像策略有潜力监测全身与局部区域治疗反应。
核心结论
- PSMA靶向分子影像策略可用于确定同时患前列腺癌和肝细胞癌患者的疾病范围,并有潜力监测全身及局部区域治疗。
研究设计与样本
- 病例报告:一名70岁男性前列腺癌患者,计划使用18F-PSMA1007行PSMA PET/CT。
主要发现
- 因肝脏摄取及磁共振相应发现,确诊肝细胞癌(G1)。
- 随访PSMA靶向PET/CT显示前列腺癌相关治疗持久缓解,而肝脏病灶进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report on a 70-year-old man affected with prostate carcinoma (PC) scheduled for prostate-specific membrane antigen (PSMA) PET/CT using 18 F-PSMA1007. Because of uptake in the liver and corresponding findings on magnetic resonance, diagnosis of hepatocellular carcinoma (HCC, G1) was established. The patient was then scheduled for antihormonal treatment for PC and locoregional therapy due to HCC. On follow-up PSMA-targeted PET/CT, we observed durable response to PC-associated therapy, whereas hepatic lesions showed progressive disease. As such, we herein report on a dual-cancer targeting molecular imaging strategy to determine disease extent in a patient affected with both PC and HCC, along with potential of monitoring both systemic and locoregional treatment.
引用
- Reiter FP, Weich A, Higuchi T, et al. Monitoring Dual-Cancer Treatment in a Patient With Prostate and Hepatocellular Carcinoma Using Prostate-Specific Membrane Antigen-Directed PET/CT. Clin Nucl Med. 2024. PMID: 38389205. doi:10.1097/RLU.0000000000005114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。